EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Stockholm3–Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up

Thorgerdur Palsdottir iD, Chiara Micoli iD, Martin Eklund, Henrik Grönberg, Fredrik Jäderling iD, Derya Tilki, Daniel W Lin, Matthew R Cooperberg iD, Scott E Eggener, Kevin C Oeffinger, Tobias Nordström iD, Hari T Vigneswaran iD

Annals of Internal Medicine · 2026-07 · 179 (7) · 988-995

DOI: 10.7326/annals-25-04753 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2026-07. Verfasst von Thorgerdur Palsdottir und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (T.P., C.M., M.E., H.T.V.). Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prostate-specific antigen (PSA) testing to screen for prostate cancer is controversial. An alternative approach, Stockholm3, combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors into a multivariable risk score. OBJECTIVE: To compare detection of clinically significant prostate cancer (csPC) using PSA and Stockholm3 in a population-based screening with short-term follow-up. DESIGN: Secondary analysis of the baseline round of the prospective STHLM3-MRI (Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies) randomized screening trial in men aged 50 to 74 years who had PSA and Stockholm3 screening. Men with abnormal screening tests (PSA ≥3 ng/mL or Stockholm3 ≥11) were randomly assigned (2:3) to systematic biopsy or magnetic resonance imaging with systematic and targeted biopsies for lesions with a Prostate Imaging Reporting and Data System score of 3 or greater. Cancer diagnosed within 2 years was identified through linkage to the Swedish National Cancer Register; cancer after a negative baseline test was classified as false negative. (ClinicalTrials.gov: NCT03377881). SETTING: Stockholm region, Sweden, 2018 to 2020. PARTICIPANTS: Men aged 50 to 74 years who had PSA and Stockholm3 screening. INTERVENTION: Prostate-specific antigen and Stockholm3 tests at baseline. MEASUREMENTS: Clinically significant prostate cancer (grade group ≥2) within 2 years of baseline. RESULTS: Among 12 670 men, 443 (3.5%) were diagnosed with csPC. Decision curve analysis showed higher net benefit for Stockholm3 versus PSA across a range of decision thresholds for biopsy, indicating fewer unnecessary biopsies and fewer missed csPC cases. Stockholm3 (≥11) had a false-negative rate of 10% (43 of 443) and a false-positive rate of 11% (1289 of 12 227), whereas PSA (≥3 ng/mL) had a false-negative rate of 26% (116 of 443) and a false-positive rate of 10% (1203 of 12 227). Correspondingly, sensitivity was 90% (95% CI, 87% to 93%) for Stockholm3 and 74% (CI, 69% to 78%) for PSA, with similar specificity (89% vs. 90%). LIMITATIONS: Participation was approximately 25% of invited men; follow-up was limited to 2 years; and the cohort was predominantly Swedish or European, which may limit generalizability. CONCLUSION: In this screening cohort with short-term follow-up, Stockholm3 provided greater clinical net benefit than PSA for detecting csPC, driven by fewer false-negative results, although follow-up was limited to 2 years. PRIMARY FUNDING SOURCE: Swedish Research Council, Swedish Prostate Cancer Society, Stockholm Region, and the Swedish Cancer Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenMagnetic Resonance ImagingEarly Detection of CancerHumansMaleMiddle AgedAgedFollow-Up StudiesSwedenBiomarkers, TumorBiopsyRisk Assessment

Substanzen

Prostate-Specific AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (T.P., C.M., M.E., H.T.V.).
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and Department of Surgery, Capio S:t Göran's Hospital, Stockholm, Sweden (H.G.).
  • Department of Diagnostic Radiology, Capio S:t Göran's Hospital, and Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden (F.J.).
  • Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Department of Urology, Koc University Hospital, Istanbul, Türkiye (D.T.).
  • Department of Urology, University of Washington Medical Center and Fred Hutchinson Cancer Center, Seattle, Washington (D.W.L.).
  • Department of Urology, University of California, San Francisco, San Francisco, California (M.R.C.).

ORCID-Profile: Thorgerdur Palsdottir, Chiara Micoli, Fredrik Jäderling, Matthew R Cooperberg, Tobias Nordström, Hari T Vigneswaran

Zitieren

APA

Palsdottir, T., Micoli, C., Eklund, M., Grönberg, H., Jäderling, F., Tilki, D., Lin, D. W., Cooperberg, M. R., Eggener, S. E., Oeffinger, K. C., Nordström, T., & Vigneswaran, H. T. (2026). Stockholm3–Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up. Annals of Internal Medicine, 179(7), 988-995. https://doi.org/10.7326/annals-25-04753

Vancouver

Palsdottir T, Micoli C, Eklund M, Grönberg H, Jäderling F, Tilki D, et al. Stockholm3–Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up. Annals of Internal Medicine. 2026;179(7):988-995. doi:10.7326/annals-25-04753

BibTeX
@article{Palsdottir2026,
  author = {Palsdottir, Thorgerdur and Micoli, Chiara and Eklund, Martin and Grönberg, Henrik and Jäderling, Fredrik and Tilki, Derya and Lin, Daniel W and Cooperberg, Matthew R and Eggener, Scott E and Oeffinger, Kevin C and Nordström, Tobias and Vigneswaran, Hari T},
  title = {Stockholm3–Magnetic Resonance Imaging Population-Based Prostate Cancer Screening Study: Two-Year Follow-up},
  journal = {Annals of Internal Medicine},
  year = {2026},
  volume = {179},
  number = {7},
  pages = {988--995},
  doi = {10.7326/annals-25-04753}
}
Kostenlos starten →